Kringle Pharma, Inc. (TYO:4884)
Japan · Delayed Price · Currency is JPY 445.00
-11.00 (-2.41%)
Aug 27, 2026, 3:30 PM JST
Kringle Pharma Balance Sheet
Financials in millions JPY. Fiscal year is October - September.
Millions JPY. Fiscal year is Oct - Sep.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Cash & Equivalents | 1,068 | 1,619 | 2,313 | 2,136 | 2,756 | 2,137 |
Cash & Short-Term Investments | 1,068 | 1,619 | 2,313 | 2,136 | 2,756 | 2,137 |
Cash Growth | -34.57% | -30.00% | 8.29% | -22.50% | 28.97% | 1.67% |
Accounts Receivable | - | - | - | 7 | - | 6 |
Other Receivables | 43.94 | 60 | 57 | 74 | 67 | 76 |
Receivables | 43.94 | 60 | 57 | 81 | 67 | 82 |
Inventory | 179.63 | 250 | 294 | 364 | 349 | 315 |
Prepaid Expenses | - | 20 | 23 | 14 | 11 | 12 |
Other Current Assets | 666.88 | 106 | 68 | 22 | 24 | 88 |
Total Current Assets | 1,958 | 2,055 | 2,755 | 2,617 | 3,207 | 2,634 |
Long-Term Investments | - | 23 | 1 | 1 | 1 | 1 |
Other Long-Term Assets | 38.55 | 1 | 1 | - | - | - |
Total Assets | 1,997 | 2,079 | 2,757 | 2,618 | 3,208 | 2,635 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Accounts Payable | 79.23 | 1 | 1 | - | 1 | - |
Accrued Expenses | - | 15 | 21 | 5 | 2 | 3 |
Current Income Taxes Payable | 1.12 | 21 | 37 | 173 | 54 | 32 |
Other Current Liabilities | 33.74 | 72 | 69 | 31 | 105 | 92 |
Total Current Liabilities | 114.08 | 109 | 128 | 209 | 162 | 127 |
Other Long-Term Liabilities | 630.43 | 662 | 522 | 388 | 258 | 2 |
Total Liabilities | 744.51 | 771 | 650 | 597 | 420 | 129 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Common Stock | 341.33 | 64 | 11 | 97 | 59 | 51 |
Additional Paid-In Capital | 3,180 | 2,888 | 2,835 | 3,095 | 3,057 | 2,755 |
Retained Earnings | -2,304 | -1,672 | -756 | -1,185 | -331 | -301 |
Comprehensive Income & Other | 35.59 | 28 | 17 | 14 | 3 | 1 |
Shareholders' Equity | 1,252 | 1,308 | 2,107 | 2,021 | 2,788 | 2,506 |
Total Liabilities & Equity | 1,997 | 2,079 | 2,757 | 2,618 | 3,208 | 2,635 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Net Cash (Debt) | 1,068 | 1,619 | 2,313 | 2,136 | 2,756 | 2,137 |
Net Cash Growth | -34.57% | -30.00% | 8.29% | -22.50% | 28.97% | 1.67% |
Net Cash Per Share | 145.60 | 236.63 | 361.45 | 396.27 | 567.55 | 514.49 |
Filing Date Shares Outstanding | 8.38 | 7.02 | 6.81 | 5.41 | 5.38 | 4.33 |
Total Common Shares Outstanding | 8.38 | 7.02 | 6.81 | 5.41 | 5.38 | 4.33 |
Working Capital | 1,844 | 1,946 | 2,627 | 2,408 | 3,045 | 2,507 |
Book Value Per Share | 149.38 | 186.38 | 309.37 | 373.88 | 518.16 | 578.13 |
Tangible Book Value | 1,252 | 1,308 | 2,107 | 2,021 | 2,788 | 2,506 |
Tangible Book Value Per Share | 149.38 | 186.38 | 309.37 | 373.88 | 518.16 | 578.13 |